Evicenter
Enhertu (fam-trastuzumab deruxtecan-nxki) in HR-positive HER2-low or HER2-ultralow breast cancer
Manufacturer
Daiichi Sankyo, Inc.; AstraZeneca Pharmaceuticals LP
Prescribing information
Enhertu (opens in a new tab)
Questions
30
Last updated

All questions

Indication: Enhertu (fam-trastuzumab deruxtecan-nxki) in HR-positive HER2-low or HER2-ultralow breast cancer

5 questions · 5 sources

Indication

What is Enhertu approved for in HER2-low breast cancer?

Testing

How are patients selected for Enhertu in HER2-low breast cancer?

Note: The indication requires HER2-low or HER2-ultralow status as determined by an FDA-authorized test.

What does HER2-ultralow mean for Enhertu eligibility?

Note: The first passage is from the DESTINY-Breast06 description in section 14.3 of the Prescribing Information.

How do pathologists test for HER2-ultralow status for Enhertu?

How common is HER2-ultralow breast cancer (Enhertu DESTINY-Breast06 screening)?

Note: Proportions among 1856 patients with HR-positive, HER2-negative metastatic breast cancer screened for DESTINY-Breast06.